AOD-9604 – Technical Brief (Research-Use-Only)
1. Identity
AOD-9604 is a modified fragment of human growth hormone (HGH), specifically designed to stimulate fat metabolism without affecting blood sugar levels. It has gained attention for its potential role in weight management and metabolic health.
2. Mechanism of Action
AOD-9604 works by:
- Stimulating lipolysis: Encourages the breakdown of stored fat.
- Inhibiting lipogenesis: Prevents the formation of new fat cells.
- Enhancing metabolic activity: Increases energy expenditure without impacting insulin sensitivity.
3. Uses
AOD-9604 is primarily researched for:
- Fat loss and weight management: Targets stubborn fat deposits.
- Metabolic disorders: Potential applications in obesity treatment.
- Joint and cartilage repair: Some studies suggest benefits for tissue regeneration.
4. Dosage
While clinical data is limited, research protocols often suggest:
- Daily subcutaneous injections: 250–500mcg per day.
- Alternative administration: Available in nasal spray form for non-invasive delivery.
- Duration: Typically used for 8–12 weeks in research settings.
5. Safety Profile
- Common side effects: Mild irritation at the injection site, occasional headaches.
- Precautions: Generally well-tolerated, but long-term effects require further study.
- No impact on IGF-1 levels: Unlike full HGH, AOD-9604 does not stimulate unwanted growth.
6. Storage Guidelines
- Before mixing: Store the lyophilized powder in a refrigerator (2–8°C / 36–46°F), protected from light.
- After mixing: Keep refrigerated and use within 30–45 days.
- Room temperature storage: Can be kept at up to 30°C (86°F) for a maximum of 21 days, but should not be returned to refrigeration afterward.
- Do not freeze: Freezing reconstituted vials can degrade the peptide’s integrity.
7 .Legality in the UK
AOD-9604 is not approved for medical use in the UK and is classified as a research chemical. It is available for scientific studies but not for human consumption. Regulatory bodies such as the MHRA (Medicines and Healthcare products Regulatory Agency) have not authorized it for therapeutic applications.
